LXRX LEXICON PHARMACEUTICALS, INC. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$2.07

Period return

+0.73 (+54.48%)

Volume

1.8M

2026-06-01O $2.17 H $2.18 L $2.07 C $2.07MA5 $2.14MA20 $2.09MA60 $1.82MA120 $1.58

6M · 124 barsYahoo Finance · USD2025-12-02 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 12.LowBUY21 days ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 03. 24.LowBUY2 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 10.LowBUY3 months ago
Citigroup: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $3.72 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Sector: Healthcare
Industry: Biotechnology
HQ: The Woodlands, TX, United States
Fiscal year end: —
Employees: 81
IPO date: —

2026. 03. 06.LowBUY3 months ago

HC Wainwright & Co.: Buy